GlaxoSmithKline CFO Interviewed on Q2 Results

LONDON, July 24, 2013 /PRNewswire/ --

Simon Dingemans, CFO, outlines the UK pharma group's Q2 performance, positive R&D pipeline news, as well as outlook and guidance for the rest of the year. 

Dingemans also gives an update on his financial strategy plan, saying, "you could see in the second quarter the benefits of the restructuring programmes and some of the financial efficiencies we've identified really contributing to drive that leverage through the P&L and accelerate earnings per share of 4% faster than the sales growth of two per cent."

The video interviews and transcripts are available now on http://video.merchantcantos.com.

MerchantCantos produces in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email [email protected] or phone +44-(0)207-936-1352.

SOURCE GlaxoSmithKline

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.